ABSTRACT
A specific and selective high-performance liquid chromatography (HPLC) technique that requires few manipulations, and is readily adaptable to analysis for a large series of samples, has been developed for the determination of the concentration of the anticancer drug doxorubicin (DXR) in rat serum and tissues. The biological samples were efficiently deproteinised and resolved from a reversed-phase nucleosil C18 column with fluorescence detection. The validation study of the proposed method was successfully carried out in an assay range of between 5 and 5000 ng/ml and was subsequently implemented in a pharmacokinetic study of DXR in Wistar rats that were treated by intravenous administration of the drug.
Subject(s)
Antibiotics, Antineoplastic/analysis , Doxorubicin/analysis , Animals , Antibiotics, Antineoplastic/pharmacokinetics , Chromatography, High Pressure Liquid , Doxorubicin/pharmacokinetics , Humans , Indicators and Reagents , Rats , Rats, Wistar , Reference Standards , Reproducibility of Results , Solutions , Spectrometry, FluorescenceABSTRACT
A study has been carried out to characterize the binding of doxorubicin to heart homogenates and subcellular fractions. The technique chosen to perform the study was equilibrium dialysis and the levels of anthracycline in the samples obtained from the dialysis were assessed using HPLC. Doxorubicin has high affinity to heart homogenates and subcellular fractions such as nuclear, mitochondrial and microsomal. The binding was saturable and dose-dependent. Doxorubicin binding is decreased in the presence of digoxin and especially verapamil.
